Edge Therapeutics (NASDAQ:EDGE) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued research reports about the company. Credit Suisse Group reiterated an “outperform” rating and set a $17.00 price objective on shares of Edge Therapeutics in a research note on Thursday. Zacks Investment Research cut Edge Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Edge Therapeutics currently has an average rating of “Hold” and an average price target of $20.00.

Shares of Edge Therapeutics (NASDAQ EDGE) opened at $12.40 on Friday. Edge Therapeutics has a 12 month low of $7.30 and a 12 month high of $12.70. The stock has a market capitalization of $382.65 and a P/E ratio of -7.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34.

Edge Therapeutics (NASDAQ:EDGE) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.11. research analysts forecast that Edge Therapeutics will post -1.7 earnings per share for the current year.

In related news, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $10.92, for a total value of $27,300.00. Following the sale, the chief executive officer now owns 102,736 shares in the company, valued at approximately $1,121,877.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Albert N. Marchio II sold 3,361 shares of the stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $10.00, for a total value of $33,610.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,361 shares of company stock worth $292,035. 36.19% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of EDGE. Voya Investment Management LLC bought a new stake in Edge Therapeutics in the 2nd quarter valued at $106,000. Russell Investments Group Ltd. raised its stake in Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,733 shares during the period. Trexquant Investment LP bought a new stake in Edge Therapeutics in the 3rd quarter valued at $130,000. Wells Fargo & Company MN raised its stake in Edge Therapeutics by 44.4% in the 3rd quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 5,307 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Edge Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,764 shares during the period. Institutional investors and hedge funds own 50.26% of the company’s stock.

WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/20/edge-therapeutics-edge-lifted-to-hold-at-bidaskclub.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.